Introduction
Apoptosis is a process of programmed cell death which eliminates unwanted or super¯uous cells from the organism, and is essential during events as distinct as embryogenesis, tissue homeostasis, regulation of the immune system, and development of the central nervous system (Ellis et al., 1991) . Cells undergoing apoptosis display a series of morphological changes including cytoplasmic shrinkage, chromatin condensation, membrane blebbing, and DNA fragmentation (Kerr et al., 1972) . The basic machinery which implements apoptosis is present in all mammalian cells, but initiation of the process is regulated by signals which can originate from either the intracellular or extracellular environment. Regulation of cell death is essential for normal development and is an important defence against the emergence of cancer. Defects in apoptotic pathways play a major role in the pathogenesis of tumours, allowing neoplastic cells to survive beyond their intended lifespans, subverting the need for endogenous growth factors, and allowing time for accumulation of genetic alterations which promote deregulated proliferation (Reed, 1999) .
Apoptosis can in some cases be dependent on de novo RNA and protein synthesis (Ellis et al., 1991) and this has led to the hypothesis that it is an active process. It is an event which, dependent on the inducing agent, is mediated by a common set of downstream regulators and eectors. One of the main regulators of apoptotic pathways is the p53 tumour suppressor protein which controls both induction of cell cycle arrest and apoptosis in response to DNA damage, growth factor deprivation, and expression of oncogenes (Brown and Pagano, 1997) . p53 has been shown to be important for the induction of apoptosis initiated by the oncogenes E2F1 and c-Myc, and the tumour necrosis factor (TNF) death receptor (Bates and Vousden, 1999) .
The Fas antigen and TNF receptor 1 (TNFR1) constitute an additional family of apoptosis eectors. These cell surface receptors, when engaged with ligand, associate with death domains of intracellular proteins such as FADD or TRADD (Fas associatedor TNFR1 associated-death domains) resulting in recruitment and activation of initiator caspases such as caspase 8 (White, 1996) . Caspase 8 activation in turn triggers proteolysis of downstream eector caspases which function as the executioners of apoptosis (Reed, 1999) . The Fas signalling pathway has been shown to be necessary for many apoptotic cascades. In particular, Myc induced apoptosis has been reported to be blocked by neutralizing antibodies to Fas ligand (Hueber et al., 1997) suggesting a role for this signalling pathway in oncogene-induced apoptosis.
Another group of apoptotic regulators includes Bcl-2 and its related family members, of which there are at least 16 in humans. This family of proteins function as pro-or anti-apoptotic molecules which, dependent on the ratio between the two subsets, determine susceptibility to apoptotic signals (Gross et al., 1999) . The Bcl-2 protein has been shown to enhance cell survival by inhibiting apoptosis under a wide variety of circumstances, suggesting a role for Bcl-2-like proteins at controlling points in apoptotic pathways (White, 1996) . Recently Bcl-2 family proteins have been shown to display structural similarity to pore-forming domains of bacterial toxins suggesting potential roles in channel formation. One cellular location where Bcl-2 proteins have been identi®ed is within the outer mitochondrial membrane. Bcl-2 family proteins have therefore been suggested to function in regulating release of cytochrome C, another trigger for the execution phase of apoptosis (Reed, 1999) . Mitochondrial release of cytochrome C functions as an alternative mechanism of initiator caspase activation. The presence of cytochrome C within the cytosol activates caspase 9 and apoptotic protease activating factor-1 (APAF-1), which in turn activate downstream eector caspases, promoting apoptotic cell death. Overexpression studies with Bcl-2 have shown that eux of cytochrome C from the mitochondria and initiation of apoptosis can be prevented, suggesting a role for Bcl-2 as a regulator of mitochondrial permeability (Yang et al., 1997) .
The c-jun gene encodes a basic region-leucine zipper (BZIP) transcription factor which has been implicated in a number of diverse cellular processes (Wisdom et al., 1999) . The Jun family of proteins form homodimers or heterodimers with Fos family members which comprise the AP-1 transcription factor, a target for cell growth, dierentiation and stress signalling pathways (Vogt and Bos, 1990 ). An essential role for cJun in cell growth control has been demonstrated using ®broblasts derived from c-Jun null mice. These cells exhibit a severe proliferation defect and are extremely inecient at G1 to S phase progression in culture, suggesting a positive role for c-Jun in cell growth control (Schreiber et al., 1999) . Many oncogenes have been described to drive a hyperproliferative response in the cell, often in the absence of endogenous growth factors and frequently cell death is observed to accompany deregulated growth. One of the best studied examples of an oncogene functioning in this manner is the c-Myc protein. Overexpression of c-Myc has been shown to induce apoptosis in growth factor-deprived ®broblasts (Evan et al., 1992) and although much of the data concerning c-Myc induced cell death is con¯icting, certain theories have emerged. These studies, dependent on the cell type used, suggest roles for p53, Fas signalling, and the mitochondria in c-Myc induced death (Prendergast, 1999) . Overexpression of the E2F1 transcription factor (DeGregori et al., 1997) and the E1A oncogene (de Stanchina et al., 1998) have also been described to induce apoptosis. Myc, E1A and E2F1 induced apoptosis all result in either upregulation or stabilization of p53, although the mechanisms utilized dier slightly. Most oncogenes which induce cell cycle deregulation also trigger apoptotic cell death. Whether this apoptosis occurs as a consequence of hyperproliferation is unclear but deregulation of key cell cycle regulated proteins can, in the case of Myc, E1A and E2F1 result in p53 induced apoptosis. c-Jun can also act as an oncogene when overexpressed, promoting cell cycle progression in addition to apoptosis (Bossy-Wetzel et al., 1997) . The oncogenic form of c-Jun, v-Jun, functions in a similar manner to the c-Myc, and E1A oncoproteins in promoting S phase entry but these cells are unable to accumulate in number in the absence of endogenous growth factor stimulation due to apoptotic cell death (Clark and Gillespie, 1997) .
To gain insight into the mechanism through which the v-Jun oncogene sensitizes cells to apoptosis, we examined the requirement for a number of key proteins which have previously been implicated in the induction of oncogene-induced cell death. Our results suggested that v-Jun does not stimulate p53 function, nor does it signal through the Fas ligand signalling pathway to trigger apoptosis induced as a consequences of mitogen withdrawal. v-Jun was observed to induce cytochrome C release from the mitochondria both as a consequence of v-Jun expression and to increase this during apoptosis, an event which could be blocked by overexpression of Bcl-2. These results suggest that the mitochondrion lies at the end point of the apoptotic cascade induced by v-Jun.
Results

Induction of apoptosis by v-Jun in the absence of serum growth factors
We have previously demonstrated that v-Jun transformed ®broblasts continue to cycle actively in the absence of serum growth factors but that a signi®cant proportion of the cycling cells undergo apoptosis and detach from the substrate under these conditions (Clark et al., 2000) . Apoptotic cells were not observed in corresponding cultures of quiescent control ®bro-blasts or in v-Jun-transformed cells cultured in serumreplete medium. To investigate this phenomenon in more detail, v-Jun-transformed cells were analysed for apoptotic characteristics at various times after transfer to low serum (LS) medium. Cells with condensed, fragmented nuclei were observed to accumulate under these conditions and¯ow cytometric terminal deoxynucleotidyl transferase nick end labelling (TUNEL) staining con®rmed they were apoptotic. After 48 h approximately 30% of v-Jun-transformed cells were apoptotic (Figure 1 ) in contrast to control chicken embryo ®broblasts (CEF) which exited the cell cycle and entered G 0 (data not shown). Apoptotic cells could be observed within 4 h of LS treatment and gradually accumulated over the course of the experiment ( Figure  1 ).
Bcl-2, v-PI 3-Kinase and v-Src inhibit v-Jun-induced apoptosis
The Bcl-2 family of proteins function as critical regulators of apoptotic pathways and act either to inhibit or promote cell death (Reed, 1998) . Overexpression of Bcl-2 has been demonstrated in many systems to block apoptosis (Yang et al., 1997 ) and therefore we chose to overexpress Bcl-2 to determine whether we could prevent cell death in v-Jun transformed CEFs. To achieve simultaneous overexpression of v-Jun and test modulators in CEFs we utilized a two vector retroviral approach. One vector (SFCV), which was replication defective, contained the gene of interest in addition to a neomycin selection marker. This was co-transfected into cells with a replication competent control retrovirus (RCAS) or RCAS v-Jun. After G418 selection this approach leads to high level expression of both genes (Clark et al., 2000) . Human Bcl-2 was retrovirally overexpressed in this manner in conjunction with v-Jun and was found to completely block apoptosis (Figure 2a) . These results suggested that down-regulation of endogenous Bcl-2 might be a potential cause of v-Jun induced apoptosis. Examination of the endogenous levels of Bcl-2 in CEFs however revealed that expression was in fact elevated in v-Jun CEF and also that no decrease occurred during LS treatment (Figure 2b, upper panel) . This increase in the baseline expression was modest relative to the levels obtained in the overexpression studies and clearly was not high enough to confer a protective eect (Figure 2b , lower panel).
Serum and growth factors have long been documented to provide survival signals to cells (Ra et al., 1993) . In this system removal of serum growth factors in the presence of the v-Jun oncogene is the trigger for apoptotic cell death. To investigate the nature of the protective signal elicited by serum growth factors we studied the eects of overexpression of two downstream eectors of growth factor receptors, Src and Phosphatidylinositol 3-Kinase (PI3K) on v-Jun induced cell death.
PI3K is a heterodimeric lipid kinase which is composed of regulatory (p85) and catalytic (p110) subunits. PI3K has been described to play roles in mitogenic signalling, inhibition of apoptosis, intracellular vesicle tracking/secretion, and regulation of actin and integrin functions (Carpenter and Cantley, 1996) . Src is a member of a family of protein tyrosine kinases which signal downstream of growth factor and integrin adhesion receptors (Schwartzberg, 1998) . Retroviral overexpression of a constitutively active Figure 1 v-Jun induces apoptosis in CEF cultured under low serum conditions. CEF and v-Jun CEF were cultured in either growth media (GM) or low serum media (LS) for 24 h prior to ®xation in 70% Ethanol/PBS. Cells were subsequently stained with Propidium Iodide and apoptotic nuclei examined by¯uorescence microscopy. Apoptotic nuclei are denoted by A's (upper panel). CEF and v-Jun CEF were cultured for the times indicated in LS media prior to harvesting of adherent and¯oating cells. Following ®xation cells were TUNEL stained and analysed by¯ow cytometry. Results presented are the mean of three independent experiments+s.e.m. (lower panel) catalytic subunit of PI3K (v-PI3K) or a mutant temperature sensitive (ts) v-Src, LA29 at the permissive temperature (Welham and Wyke, 1988) in combination with v-Jun resulted in a partial suppression of apoptosis (Figure 3a, b) . The eects of v-Src and v-PI3K on apoptotic cell death were quantitatively very similar, suggesting the possibility that both of these proteins may act in the same linear signalling pathway.
Previous reports have demonstrated that selective inhibitors of PI3K function block growth factor dependent survival in PC12 cells (Yao and Cooper, 1995) . To address whether endogenous PI3K activity was required for the protective eect of serum growth factors, control and v-Jun-transformed CEFs were treated with the PI3K inhibitor LY294002. Cells at dierent stages of con¯uency were treated with LY294002 for 24 h and the rates of either apoptosis or DNA synthesis measured (Figure 4a ). These studies demonstrated that inhibition of PI3K activity triggered apoptosis in v-Jun transformed CEF in the presence of serum, but had little or no eect in control cells. The levels of apoptosis observed in untreated cells at dierent stages of con¯uency were equivalent to the baseline apoptosis observed in CEFs (data not shown). Interestingly, we observed that the rate of apoptosis appeared to increase as the proportion of S phase cells decreased. We have previously demonstrated a decrease in the proportion of S phase cells when either v-Jun or control CEF cultures reach high densities (Clark and Gillespie, 1997) . Since this decrease is accompanied by an increase in the proportion of G1 phase cells, this could indicate a more stringent requirement for PI3K activity to suppress apoptosis during the G1 phase of the cell cycle. Alternatively it is equally plausible that the apoptotic eects of LY294002 occur independently of its eects on the cell cycle.
Studies with ®broblasts cultured under LS conditions showed that inhibition of PI3K activity by LY294002 greatly enhanced the spontaneous rate of apoptosis in v-Jun expressing ®broblasts ( Figure 4b ). PI3K activity was also required for survival in control ®broblasts rendered quiescent by serum starvation, however the levels of apoptosis were substantially lower than those observed in v-Jun transformed ®broblasts under the same conditions.
One important downstream eector of PI3K is the serine/threonine kinase Akt/PKB. It is activated preferentially by growth factors that promote survival (Shimizu and Hunt, 1996) . Akt functions as a survival factor by phosphorylating and inactivating components of the apoptotic machinery, including the pro-apoptotic Bad protein (Brunet et al., 1999) . To determine whether LY294002 was eectively inhibiting signals downstream from PI3K we examined the levels of phosphorylated Akt, a substrate for PI3K. These results demonstrated a substantial reduction in phosphorylated Akt following LY294002 treatment and that this inhibition could be maintained over a 48 h period ( Figure 4c ). Since inhibition of PI3K activity could trigger apoptosis in v-Jun transformed cells exposed to serum, we examined whether a loss of Akt as a result of serum withdrawal contributed to vJun induced apoptosis. No signi®cant reduction in the level of active Akt was observed after transfer to LS in either control or v-Jun expressing CEFs (Figure 4d ), suggesting that spontaneous loss of phosphorylated Akt is unlikely to be the critical initiating event triggered by serum withdrawal.
v-Jun apoptosis is associated with cytochrome C release from mitochondria
One recent function ascribed to the anti-apoptotic members of the Bcl-2 family was as integral membrane proteins present in mitochondrial, endoplasmic reticulum, and nuclear membranes (Gross et al., 1999) . Within the mitochondria Bcl-2 has been postulated to function as a guard preventing cytochrome C release and thus preventing activation of the downstream eector caspases (Yang et al., 1997) . Release of cytochrome C from the mitochondria has been observed as a consequence of c-Myc induction (Juin et al., 1999) .
S-100 extracts were prepared from v-Jun CEFs and the levels of cytochrome C within the cytosolic fractions of these cells examined. Although the baseline levels of cytosolic cytochrome C were already modestly elevated in growing v-Jun CEF compared to control cells (GM), a further substantial increase in released cytochrome C was observed during the induction of apoptosis in these cells (Figure 5a ). These cytosolic extracts were not contaminated with membrane fractions as determined by the absence of the speci®c membrane component cytochrome oxidase subunit IV (Figure 5b ). Co-expression of Bcl-2 in conjunction with v-Jun decreased the levels of cytosolic cytochrome C (Figure 5b ), potentially explaining the protective eect. These results suggest a role for the mitochondria as a necessary component of the apoptotic cascade.
Dominant negative FADD does not block v-Jun-induced apoptosis
Fas is a transmembrane death receptor characterized by the presence of a death domain within the cytoplasmic region, which has been shown to trigger apoptosis upon binding of Fas ligand (Vercammen et al., 1998) . Within the cytoplasm Fas associates with the adaptor protein FADD through its death domain (DD) and recruits caspase 8 via its death eector domain (DED) resulting in the autocatalytic activation of caspase 8 and subsequent activation of eector caspases. Fas signalling has previously been implicated in oncogene-induced apoptosis (Hueber et al., 1997) . Embryo ®broblasts generated from Fas or Fas ligand de®cient mice were shown to be less sensitive to apoptosis induced by c-Myc suggesting a role for this signalling pathway in apoptosis triggered by Myc.
To investigate the possible role of FADD signalling in v-Jun induced cell death we retrovirally overexpressed a dominant negative mutant FADD molecule, which consisted of GFP fused to the carboxyterminal DD (Wajant et al., 1998) has been observed in cells expressing Myc (Hueber et al., 1997) . Expression of the dominant negative FADD construct blocked this Fas induced cell killing suggesting ecient blockage of this signalling pathway. These studies on Fas function reveal that expression of v-Jun appears to sensitize CEF to Fas induced apoptosis but that this pathway does not contribute to apoptosis occurring as a consequence of mitogen deprivation.
v-Jun-induced apoptosis is not associated with stabilization of p53 p53 has been observed to mediate apoptosis in many cell types and several dierent stimuli trigger this response (Bates and Vousden, 1999) . Some of the initiators of p53 dependent apoptosis include withdrawal of growth factors and expression of oncogenes (Hermeking and Eick, 1994) , making p53 a potential target of the v-Jun cell death pathway.
Previously we had demonstrated that v-Jun transformation can override the mitogen dependence of Rb phosphorylation and as a consequence deregulate E2F1 activity (Clark et al., 2000) . To address whether deregulated cell cycle progression could induce apoptosis mediated by p53 stabilization, we examined whether p53 accumulated as a result of cell transformation by v-Jun. No increase in p53 protein was observed either in growing CEF as a consequence of v-Jun expression or following LS treatment (Figure 7a ). UVC irradiation of v-Jun CEFs revealed that p53 could be stabilized in these cells as a consequence of DNA damage. These results suggest that v-Jun does not induce apoptosis via p53 stabilization. Studies using a synthetic p53 reporter construct also demonstrated no 
Disruption of p53 function does not inhibit v-Jun-induced cell death
To determine whether p53 function was required for apoptotic cell death in v-Jun transformed cells we sought to compromize p53 function using HPV16 E6 protein. The E6 protein of HPV types 16 and 18 functions to promote the degradation of p53 (Schener et al., 1990) and can thus be used to inhibit p53 function. Retroviral overexpression of E6 in combination with vJun was observed to have no eect on the levels of cell death induced by growth factor starvation (Figure 7b) . Expression of the E6 protein in CEFs could not be detected by conventional Western blotting or immunoprecipitation, but could be weakly detected by immunouorescence (data not shown). Examination of the eect of E6 expression suggested that p53 induction as a consequence of UVC irradiation was impaired in E6 expressing cells relative to the induction of p53 observed in control cells. Further evidence for disruption of p53 function by E6 was obtained using synthetic p53 responsive promoters which demonstrated an eightfold reduction in p53 transcriptional activity following E6 expression (data not shown). These results suggest that accumulation and/or activation of p53 is unlikely to be an important component of the mechanism through which v-Jun sensitizes cells to apoptosis.
v-Jun-induced apoptosis is not blocked by inhibition of caspase function
Caspases have a well established role in the apoptotic process, although caspase-independent apoptotic pathways also exist within the cell (Gross et al., 1999) . To investigate whether caspases were required for v-Jun induced apoptosis, cells were treated with a pancaspase inhibitor (ZVAD-fmk) and the eect on cell death examined. Figure 8a demonstrates that ZVADfmk had little, if any, eect on the incidence of apoptosis (as measured by TUNEL), although the induction of apoptosis was slightly delayed. Microscopic examination of these cells con®rmed that they also displayed the classic morphological characteristics of apoptosis (data not shown), a function described, in certain circumstances, to be blocked by caspase inhibition (Xiang et al., 1996) . Examination of FAK, one of the known targets of caspase cleavage in transformed CEF (Crouch et al., 1996) , demonstrated that FAK cleavage was blocked in cells treated with ZVAD-fmk. In contrast to this cleavage of lamin B1, a caspase 6 substrate was not eectively blocked following ZVAD-fmk treatment (Figure 8b ). These results suggest that v-Jun either utilizes a caspaseindependent apoptosis or alternatively that it involves activation of caspases which are not eciently blocked by the ZVAD-fmk inhibitor.
Discussion
Previously we had demonstrated that v-Jun-transformed ®broblasts divide more rapidly than control CEFs and that this accelerated cell cycle progression was accompanied by apoptotic cell death (Clark and Gillespie, 1997) . Normal ®broblasts, when cultured in the absence of serum mitogens, exit the cell cycle and enter a reversible state of quiescence. In contrast, v-Jun CEFs continue to traverse the cell cycle, but cycling in the absence of mitogenic stimulation induces cell death. When v-Jun CEFs were cultured in serum replete media apoptotic cell death was not observed, suggesting that v-Jun sensitizes cells to apoptosis but that this is normally suppressed by survival signals emanating from serum growth factors. In this study we endeavoured to gain an insight into the mechanism of v-Jun induced apoptosis sensitization. The approach used was to co-express a number of potential modulators of distinct apoptotic pathways and to determine whether the incidence of apoptosis was aected by these interventions.
Initially we examined the role of Bcl-2 in v-Juninduced apoptosis. Bcl-2 has been demonstrated to be a very potent inhibitor of apoptosis in a wide range of situations. Overexpression of human Bcl-2 in conjunction with v-Jun in CEFs was observed to completely abolish apoptosis, suggesting a role for the Bcl-2 family of proteins in preventing v-Jun-induced cell death. As v-Jun-induced apoptosis was triggered as a consequence of mitogen withdrawal we examined the eect of signals arising from growth factor receptors on the levels of apoptosis in v-Jun CEFs. Overexpression of the kinases v-PI3K and v-Src were shown to have similar eects on reducing the levels of cell death observed when expressed in conjunction with v-Jun, although they were not as eective at suppressing apoptosis as ectopic Bcl-2 expression. The converse experiment was also performed where PI3K activity was inhibited in serum replete media. This demonstrated a requirement for PI3K activity in growing vJun CEFs in addition to v-Jun CEFs cultured in LS conditions. Surprisingly we observed that control cells required PI3K activity for survival during quiescence but not during proliferation. This dierence in requirement for PI3K activity for survival in control The results presented in this study demonstrate that continuous survival signals are required to suppress apoptosis in v-Jun-transformed cells. Growth factors have been shown to exert protective eects in many dierent systems. For example in c-Myc transformed ®broblasts insulin-like growth factors (IGFs), platelet derived growth factor (PDGF), and endothelin-1 have all been observed to protect from apoptosis under low serum conditions (Homan and Liebermann, 1998) . The observation that signalling from growth factor receptors induced v-Jun-induced apoptosis suggested the possibility that spontaneous loss of PI3K or downregulation of Bcl-2 might contribute to apoptosis. During the course of low serum treatment in v-Jun CEFs however we observed no signi®cant changes in the levels of phosphorylated Akt, a downstream target of PI3K, suggesting that spontaneous loss of this survival signal is unlikely to initiate v-Jun driven cell death. In addition, examination of the baseline levels of Bcl-2 in CEFs revealed that the Bcl-2 protein was not downregulated, but by contrast was upregulated in vJun CEFs. Thus, although constitutive signalling through growth factor receptors and ectopic expression of Bcl-2 can partially or completely suppress apoptosis, spontaneous loss of these signals are unlikely to play a major role in initiating v-Jun induced apoptosis.
Recently the Bcl-2 family of proteins have been described to function in regulating mitochondrial permeability (Gross et al., 1999) . In addition, Akt, a downstream target of PI3K has also been suggested to function in regulating mitochondrial release of cytochrome C (Kennedy et al., 1999) . The inhibition of apoptosis as a consequence of overexpression of Bcl-2 or PI3K activity suggested that v-Jun may modulate cytochrome C release from the mitochondria. Examina- tion of cytosolic extracts prepared from v-Jun-transformed cells revealed an accumulation of cytosolic cytochrome C as a consequence of v-Jun expression. A more considerable increase in cytosolic cytochrome C was observed during initiation of apoptosis, which could be prevented by Bcl-2 overexpression. Recently a role for cytochrome C release in c-Myc-induced apoptosis has been described (Juin et al., 1999) . In Myc-expressing cells release of cytochrome C alone was not sucient to drive apoptosis, but appeared to sensitize the cells to apoptosis. Our data are consistent with the operation of a similar mechanism in v-Jun CEF.
p53 is a key controller of decisions determining whether, in response to stress or damage, the cell undergoes growth arrest or apoptosis. An accumulation of evidence is now suggesting a role for p53 in many oncogene induced cell death pathways. Myc, E1A, Ras and E2F1 have all been shown to induce accumulation p53 as a consequence of p19
Arf induction. Although the mechanisms utilized by these proteins dier slightly they all result in apoptotic cell death driven in part by p53 stabilization (de Stanchina et al., 1998; Zindy et al., 1998) . Recently this has been suggested as a major mechanism of apoptosis occurring as a consequence of oncogene-induced hyperproliferation. To address the possible role of p53 in v-Jun-induced apoptosis we looked for evidence of spontaneous upregulation of p53 in v-Jun CEF, and reduced apoptosis following inhibition of p53 function by the HPV16 E6 protein.
We observed no increase in the baseline levels of p53 in v-Jun CEF in the presence of serum growth factors suggesting that expression of the v-Jun oncogene does not trigger p53 stabilization or expression. Induction of apoptosis in v-Jun CEFs as a consequence of serum growth factor withdrawal demonstrated no additional increase or stabilization of the p53 protein. These results suggested that v-Jun was not promoting apoptosis via a pathway which requires p53 upregulation or stabilization. We further investigated the possible role of p53 function using the E6 protein, which functions by binding p53 and promoting ubiquitin-mediated degradation by the 26S proteasome complex (Schener et al., 1990) . This revealed that E6 expression had no eect on the levels of cell death occurring as a consequence of LS treatment. Taken together, these results argue that p53 plays little, if any role in v-Jun induced apoptosis.
In comparison, studies analysing c-Myc induced apoptosis have been con¯icting with regard to the role of p53 in this response. Mouse embryo ®broblasts from p53 null mice are less sensitive to apoptosis induced by c-Myc (Hermeking and Eick, 1994) , although expression of either SV40 T antigen, which inactivates p53 and pRb, or the E1B 55 kDa protein, which inactivates p53, were shown to have no eect on the ability to induce apoptosis in established Rat1 cells (Harrington et al., 1994; Lenahan and Ozer, 1996) . The connection between p53 and c-Myc appears to be complex. Some of this complexity may be due to the dierent cell types used in the above studies but it has been proposed that c-Myc and p53 may interact with some common apoptosis eector protein. Although the issue is complex for c-Myc it appears that p53 is not modulated, nor is its activity essential for v-Jun to induce an apoptotic pathway.
To address whether signalling through the Fas ligand signalling pathways was involved in triggering apoptosis in v-Jun-transformed cells we disrupted this pathway by expressing a dominant negative FADD protein. Expression of this protein, which can block Fas recruitment of FADD and thus activation of caspase 8, was observed to have no eect on the levels of apoptosis in v-Jun expressing cells. This data is in contrast to reports on c-Myc induced cell death where neutralizing antibodies against Fas ligand, dominant negative FADD constructs, or embryo ®broblasts from mice de®cient in either the Fas or Fas ligand genes were less sensitive to apoptosis induced by c-Myc suggesting that c-Myc sensitizes cells to death in part via the Fas pathway (Hueber et al., 1997) .
Most apoptotic processes require the action of the caspases as an eector mechanism of apoptosis. Within this study we have demonstrated that apoptosis induced by the v-Jun oncoprotein was not blocked by the caspase inhibitor ZVAD-fmk. Many other studies have reported caspase-independent apoptotic cascades (Nunez et al., 1998; Xiang et al., 1996) but in general these cell death processes, although they show perturbations in mitochondrial function and DNA condensation, do not show the morphological features of apoptosis. DNA fragmentation was apparent in our system as demonstrated by TUNEL staining. In addition the key morphological features ascribed to apoptotic cells (chromatin condensation and fragmented nuclei) were apparent in v-Jun CEF treated with ZVAD-fmk, a feature which is absent in many ZVADfmk treated cells. These results suggest that DNA degradation and nuclear condensation may be occurring independently of the eector caspases or independently of caspases which are sensitive to ZVAD-fmk inhibition. Blockage of caspase function using cell permeable inhibitors during c-Myc induced apoptosis resulted in inhibition or delay of the biochemical and morphological features of apoptosis, although the commitment to cell death was not blocked (McCarthy et al., 1997) . Recently evidence has emerged for the presence of a mitochondrial apoptosis inducing factor (AIF). AIF is a caspase-independent death eector normally found in the mitochondria, but which translocates to the nucleus when apoptosis is induced (Susin et al., 1999) . AIF can function to induce cytochrome C release from the mitochondria but additional evidence exists that AIF alone can induce chromatin condensation and DNA fragmentation. Further studies are required to determine whether vJun utilizes a caspase-independent mechanism of apoptotic cell death or whether caspases which are not eciently blocked by ZVAD-fmk are responsible for the apoptotic morphology observed in these cells.
Within this study we have demonstrated that v-Jun induces apoptotic cell death initiated by mitogen withdrawal. Our premise was that v-Jun expression may sensitize cells to apoptotic stimuli and we have determined that survival signals such as Bcl-2 and PI3K can block this cell death. Expression of v-Jun appeared to stimulate cytochrome C release from the mitochondria, an event which was not restricted to apoptosis initiation. The Myc oncogene also appears to induce mitochondrial dysfunction suggesting that oncogenes may utilize a similar pathway to trigger apoptosis, although the mechanism used remains unknown. One possibility is that oncogene induced cell cycle defects may account in part towards apoptosis sensitization. Recent hypotheses to explain cell cycle deregulation by c-Jun have been con¯icting. One report suggests that c-Jun null mice exhibit severe proliferation defects as a consequence of a reduced activation of the D-and E-type cyclin dependent kinase activities (Schreiber et al., 1999) . In contrast to this a second group similarly used ®broblasts derived from c-Jun null embryos and suggest that c-Jun modulates G1 expression by transcriptional activation of the cyclin D1 gene (Wisdom et al., 1999) . They also demonstrate that overexpression of c-Jun protects from UV-induced apoptosis whereas others have shown that activation of a conditional allele of c-Jun induced apoptosis in ®broblasts (Bossy-Wetzel et al., 1997) . As these discrepancies demonstrate, the data concerning the mechanism of c-Jun induced cell cycle deregulation and apoptosis are not yet apparent and it remains to be demonstrated whether there is any link between the two processes.
We have demonstrated that v-Jun induces cytochrome C release from the mitochondria as a component of its apoptotic response. We suggest that v-Jun may belong to a category of oncogenes which may induce apoptotic cell death through a distinct mechanism involving mitochondrial dysfunction. Indeed the case with c-Myc-induced apoptosis suggests that Fas and p53 signalling pathways have no eect on the release of cytochrome C (Juin et al., 1999) , suggesting that oncogenes may function in some independent manner to disrupt mitochondrial function. Historically many oncogene-expressing cells have been demonstrated to consume glucose and overproduce lactic acid resulting in energy generation without the need for oxygen. This phenomenon, known as the Warburg eect, has been described for c-Myc and HRas-transformed cells (Dang and Semenza, 1999) . In Myc-Ras transformed rat embryo ®broblasts hypoxia was observed to induce an acidic environment and subsequent apoptosis. This eect could be reduced when extracellular pH was buered to 7.0 suggesting that acidosis is a potent eector of apoptosis under hypoxic conditions. Recently changes in lactate production in the presence of Myc have been shown to be inhibited by Bcl-2 (Papas et al., 1999) . Expression of the v-Jun oncogene, which induces similar medium acidi®cation as the Myc and Ras oncogenes, was observed to induce an apoptotic pathway which was dependent on the mitochondria and could be blocked by Bcl-2 (Figure 9 ). What is unclear at present is whether changes in cellular metabolism, which may induce oxidative stress and mitochondrial dysfunction, have a direct causal eect or are a consequence of the induction of apoptosis. Until the apoptotic signals which converge at the mitochondria are identi®ed this remains an open question.
Materials and methods
Cell culture
Cultures of primary chicken embryo ®broblasts (CEFs) were grown in DMEM medium supplemented with 10% newborn calf serum, 2% heat-inactivated chicken serum, or in low serum (LS) conditions containing 0.2% newborn calf serum only. Medium was replaced on growing cultures every 24 h.
Retroviral vectors and infection
ASV17 virus was regenerated as described previously (Clark and Gillespie, 1997) . GFPDFADD was excised from pCDNA3.1 GFPDFADD (received from Harald Wajant, University of Stuttgart, Germany) as a HindIII/NotI (end®lled) fragment and cloned into SFCV between HindIII and EcoRI (end-®lled) to generate SFCV GFPDFADD. SFCV viruses were regenerated using RCAS or RCAS v-Jun as helper viruses. Primary CEF were transfected with the appropriate retroviral DNA combinations, and passaging in the presence of G418 (Gibco BRL) until uniform infection was obtained. RCAS vPI3K was a gift from Peter Vogt (Scripps Research Institute, La Jolla, CA, USA), RCAS Bcl-2 was obtained from Stephen Hughes (National Cancer Institute, Frederick, Maryland, USA) and SFCV LA29 was obtained from Margaret Frame (Beatson CRC Laboratories, Glasgow, UK). SFCV E6 was generated by PCR from HPV16 DNA. Oligos were designed to incorporate a Myc tag at the N-terminus with HindIII and EcoRI sites (5' cccaagct tgggatggagcaaaagctcatttctgaagaggacttgatgcaccaaaagagaactgcaatgttg 3' and 5' ccggaattccggtgcatgattacagctggg 3') and the resultant PCR product cloned into HindIII/EcoRI sites within SFCV.
Preparation of cell extracts and Western blotting
Whole cell extracts were prepared from CEF cultures, resolved by SDS ± PAGE and analysed by Western blotting as described previously (Clark and Gillespie, 1997) . Nuclear Figure 9 Possible mechanism of v-Jun induced apoptosis. Removal of serum growth factors in the presence of v-Jun results in release of cytochrome C from the mitochondria, which can be blocked by Bcl-2. The apoptotic signals upstream of cytochrome C release do not utilize the p53 or Fas/FADD/caspase 8 signalling pathways and remain unknown at present. The mechanism of cell death is complex but may involve metabolic imbalance or cell cycle deregulation occurring as a consequence of oncogene expression extracts were prepared as described previously (Schreiber et al., 1989) . Cytosolic and membrane extracts were prepared by centrifugal separation as follows; cells were rinsed in PBS prior to resuspension in ®ve volumes of Buer A (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM Dithiothreitol, and 0.1 mM Phenylmethylsulphonyl Fluoride). Samples were gently lysed by incubation in a sonicating water bath for 5 min followed by two rounds of centrifugation at 750 g for 10 min. Supernatants were further centrifuged at 10 000 g for 15 min. The resultant membrane pellet was resuspended in Buer A and the supernatant centrifuged at 100 000 g for 1 h and the resulting S-100 supernatant collected.
Antisera used for Western blotting were as follows; anticytochrome C (Pharmingen 65981A), anti-FADD (Transduction Laboratories F36620), anti-p53 (Hybridoma clone pAB240 from David Lane, Dundee, UK), anti-Bcl-2 (Transduction Laboratories B46620), anti-Akt and phosphoAkt (New England Biolabs 9270), anti-COX IV (Molecular Probes A-6409), anti-FAK (Transduction Laboratories F15020), anti-Src (Upstate Biotechnologies 05-185), antip110a (Santa Cruz sc1331), anti-lamin B1 (Zymed Laboratories 33-2200) and anti-Jun and anti-Gag antisera have been described previously (Kilbey et al., 1996) . Agonistic Fas antibody was obtained from Transduction Laboratories (F22120) and mouse IgG from Sigma (M7023). The chemicals used were as follows: LY294002 (440202) and ZVAD-FMK (627610) were obtained from Calbiochem, biotin-16-2'-deoxyuridine-5'-triphosphate (1093 070) and terminal transferase (220 582) were obtained from Boehringer Mannheim.
Flow cytometric assays
For TUNEL analysis¯oating and adherent CEFs were harvested and ®xed in 1% Formaldehyde/PBS for 15 min on ice. Cells were subsequently centrifuged and resuspended in 1 ml 70% Ethanol/PBS and stored at 48C until stained. For TUNEL staining the method of Gorczyca was followed (Gorczyca et al., 1993) . For cell cycle analysis or morphological characterization of apoptosis, ®xed cells were resuspended in PBS containing 250 mg/ml RNAse A and 1 mg/ml Propidium Iodide. Flow cytometric analysis was performed using a Becton Dickinson FASCAN and morphological analysis of nuclei was examined using a Zeiss Axioskop. To quantitate the proportion of cells actively synthesizing DNA, BrdU was added to growing cultures at a concentration of 25 mM for 1 h prior to harvest. Cells were labelled as described previously (Clark and Gillespie, 1997) .
